ORIC-944 for metastatic prostate cancer after hormone therapy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This early-phase trial tests ORIC-944 to see how well it works and what dose is safest for metastatic prostate cancer that has progressed after hormone-targeted pills. It may help people whose cancer has stopped responding to prior prostate cancer hormone treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic prostate cancer that has spread beyond the prostate
- You’ve had both testicles removed, or you will continue a hormone shot/pill (GnRH) to keep testosterone at very low “castrate” levels
- Your prior prostate cancer treatments fit one of the trial’s specific plans (the trial checks which hormone pills and how many chemo treatments you’ve had)
- Cancer is clearly getting worse based on specific PSA, scan, or bone/soft-tissue progression rules
- You can have skin and core tumor biopsies during the study
- Your day-to-day function is good (ECOG 0–1) and your organs (blood, kidney, liver) meet safety lab requirements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This trial tests two drugs—talazoparib and enzalutamide—given together to men whose metastatic prostate cancer has worsened after treatment with abiraterone (Zytiga). The goal is to see if this combination can help control the cancer.
This study tests an experimental pill called rinzimetostat (ORIC-944) for men with advanced prostate cancer that has spread and stopped responding to abiraterone. It may offer a new option if you have not had many other treatments yet.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
This trial studies how well the combination of olaparib and abiraterone works for men with advanced prostate cancer that has stopped responding to hormone therapy. If you are already taking or planning to take this combination, researchers want to learn more about its long-term benefits and safety.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.